György M. Keserű
György M. Keserű
Verified email at - Homepage
Cited by
Cited by
Encyclopedia of Pharmaceutical Technology: Volume 6
J Swarbrick
CRC press, 2013
The role of ligand efficiency metrics in drug discovery
AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds
Nature reviews Drug discovery 13 (2), 105-121, 2014
The influence of lead discovery strategies on the properties of drug candidates
GM Keserü, GM Makara
nature reviews Drug Discovery 8 (3), 203-212, 2009
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
MM Hann, GM Keserü
Nature reviews Drug discovery 11 (5), 355-365, 2012
Expanding the medicinal chemistry synthetic toolbox
J Boström, DG Brown, RJ Young, GM Keserü
Nature Reviews Drug Discovery 17 (10), 709-727, 2018
Hit discovery and hit-to-lead approaches
GM Keserű, GM Makara
Drug discovery today 11 (15-16), 741-748, 2006
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ...
Nature communications 11 (1), 1-11, 2020
Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia
GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ...
Journal of medicinal chemistry 59 (18), 8189-8206, 2016
GPCRdb in 2021: integrating GPCR sequence, structure and function
AJ Kooistra, S Mordalski, G Pándy-Szekeres, M Esguerra, A Mamyrbekov, ...
Nucleic Acids Research 49 (D1), D335-D343, 2021
Impact of lipophilic efficiency on compound quality
A Tarcsay, K Nyíri, GM Keserű
Journal of medicinal chemistry 55 (3), 1252-1260, 2012
Thermodynamics guided lead discovery and optimization
GG Ferenczy, GM Keserű
Drug discovery today 15 (21-22), 919-932, 2010
A high throughput luminescent assay for glycogen synthase kinase-3 β inhibitors
A Baki, A Bielik, L Molnár, G Szendrei, GM Keserü
Assay and drug development technologies 5 (1), 75-84, 2007
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods
GM Keserü
Bioorganic & medicinal chemistry letters 13 (16), 2773-2775, 2003
Contributions of molecular properties to drug promiscuity: miniperspective
Á Tarcsay, GM Keserű
Journal of medicinal chemistry 56 (5), 1789-1795, 2013
Recent advances in the prediction of blood–brain partitioning from molecular structure
M Lobell, L Molnár, GM Keserü
Journal of pharmaceutical sciences 92 (2), 360-370, 2003
Fully flexible low-mode docking: application to induced fit in HIV integrase
GM Keserû, I Kolossváry
Journal of the American Chemical Society 123 (50), 12708-12709, 2001
Pharmacologic inhibition of STAT5 in acute myeloid leukemia
B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ...
Leukemia 32 (5), 1135-1146, 2018
Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening
R Kiss, B Kiss, Á Könczöl, F Szalai, I Jelinek, V László, B Noszál, A Falus, ...
Journal of medicinal chemistry 51 (11), 3145-3153, 2008
In silico and ex silico ADME approaches for drug discovery
F Darvas, G Keseru, A Papp, G Dorman, L Urge, P Krajcsi
Current topics in medicinal chemistry 2 (12), 1287-1304, 2002
Virtual screening for β-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228
T Polgár, GM Keserü
Journal of Medicinal Chemistry 48 (11), 3749-3755, 2005
The system can't perform the operation now. Try again later.
Articles 1–20